Palbociclib was the first FDA approved CDK4/6 inhibitor and highly efficacious in the treatment of HR+/HER2- breast cancers, followed by the structurally related molecules ribociclib and abemaciclib7–11. The gene discussed is CDK4; the disease is breast carcinoma.